Inhibition of DPP-4 with vildagliptin improved insulin secretion in response to oral as well as "isoglycemic" intravenous glucose without numerically changing the incretin effect in patients with type 2 diabetes

Irfan Vardarli, Michael A Nauck, Lars D Köthe, Carolyn F Deacon, Jens Juul Holst, Anja Schweizer, James E Foley

Research output: Contribution to journalJournal articleResearchpeer-review

55 Citations (Scopus)

Abstract

Dipeptidyl peptidase-4 (DPP-4) inhibitors block the degradation of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide. The aim of the present study was to quantitatively assess the incretin effect after treatment with the DPP-4 inhibitor vildagliptin (V) or placebo (P) in patients with type 2 diabetes.
Original languageEnglish
JournalJournal of Clinical Endocrinology and Metabolism
Volume96
Issue number4
Pages (from-to)945-954
Number of pages10
ISSN0021-972X
DOIs
Publication statusPublished - 2011

Keywords

  • Adamantane
  • Administration, Oral
  • Adult
  • Aged
  • Blood Glucose
  • Cross-Over Studies
  • Diabetes Mellitus, Type 2
  • Dipeptidyl Peptidase 4
  • Dipeptidyl-Peptidase IV Inhibitors
  • Female
  • Glucose
  • Humans
  • Incretins
  • Injections, Intravenous
  • Insulin
  • Male
  • Middle Aged
  • Nitriles
  • Pyrrolidines
  • Up-Regulation

Cite this